Edition:
United States

Cempra Inc (CEMP.O)

CEMP.O on Nasdaq

3.78USD
10:51am EDT
Change (% chg)

$-0.03 (-0.66%)
Prev Close
$3.80
Open
$3.85
Day's High
$3.90
Day's Low
$3.70
Volume
624,909
Avg. Vol
1,477,831
52-wk High
$26.95
52-wk Low
$2.55

CEMP.O

Chart for CEMP.O

About

Cempra, Inc. is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $199.51
Shares Outstanding(Mil.): 52.50
Dividend: --
Yield (%): --

Financials

  CEMP.O Industry Sector
P/E (TTM): -- 142.93 17.37
EPS (TTM): -2.16 -- --
ROI: -56.23 2.34 -5.89
ROE: -64.15 0.22 -5.30

BRIEF-Cempra Q1 loss per share $0.44

* Cempra reports first quarter 2017 financial results and provides corporate update

Apr 28 2017

BRIEF-Cempra retains Morgan Stanley to lead review of strategic business options

* Cempra retains Morgan Stanley to lead review of strategic business options

Mar 13 2017

BRIEF-Cempra Q4 loss per share $0.60

* Cempra provides corporate update and reports fourth quarter and full year 2016 financial results

Feb 28 2017

Cempra's bacterial skin infection drug clears study, shares surge

Cempra Inc said on Friday that its experimental oral drug to treat acute bacterial skin infections cleared a late-stage study, bringing the antibiotic developer one step closer to getting its first drug to market.

Feb 24 2017

UPDATE 2-Cempra's bacterial skin infection drug clears study, shares surge

* Cempra shares rise 38 pct, set for best day ever (Adds details, analyst comment)

Feb 24 2017

BRIEF-Cempra’s fusidic acid achieves primary endpoint in phase 3 study of Absssi

* Cempra’s fusidic acid achieves primary endpoint in phase 3 study of Absssi

Feb 24 2017

REFILE-Cempra's bacterial skin infection drug succeeds in key study

Feb 24 Cempra Inc said on Friday that its experimental drug to treat acute bacterial skin infections met the main goal of a late-stage study, sending the company's shares surging 41 percent in premarket trading.

Feb 24 2017

FDA rejects Cempra's antibiotic for pneumonia, shares sink

Cempra Inc said on Thursday the U.S. Food and Drug Administration had rejected its antibiotic for community-acquired bacterial pneumonia (CABP), citing inadequate data on the drug's impact on the liver and manufacturing issues.

Dec 29 2016

More From Around the Web

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,416 -5.50
Johnson & Johnson (JNJ.N) $127.47 +0.47
Pfizer Inc. (PFE.N) $32.22 -0.25
Roche Holding Ltd. (ROG.S) CHF268.00 +1.00
Roche Holding Ltd. (RO.S) CHF268.00 +1.25
Abbott Laboratories (ABT.N) $43.58 +0.42
Bayer AG (BAYGn.DE) €116.80 -0.15
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.81 -0.57
AstraZeneca plc (AZN.L) 5,127.00 +8.00

Earnings vs. Estimates